Register | Forgot Your Password? | Close

(AP) - NEW APPROVALS: Five more countries will allow sales of Pfizer Inc.'s new twice-a-day pill for controlling rheumatoid arthritis, Xeljanz: Russia, Argentina, Kuwait, United Arab Emirates and Switzerland.

THE MARKET: Nearly 24 million people worldwide suffer from rheumatoid arthritis, a painful, often disabling immune disorder.

THE COMPETITION: Xeljanz could win patients away from pricey, injected biologic drugs approved for multiple immune disorders, including Enbrel, Humira and Remicade. They cost roughly $2,500 a month, compared to just over $2,000 for Xeljanz. It's heavily advertised in the U.S., where it was launched in November, but has dangerous potential side effects.

(Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
share this story:
Attention Comment Users: We have recently changed our comments boards.
We would like you to be part of the conversation and The Voice of Arizona by logging in with your Facebook, Twitter, Google+ or Disqus account. Existing KTAR (Arizona Sports) account members will need to create a Disqus account or use one of the aforementioned social media logins. Thank you.
comments powered by Disqus